Preimplantation Genetic Testing Market Size (2024 - 2029)

The preimplantation genetic testing market is projected to experience significant growth, driven by increased awareness among parents about diagnostic advancements and the rising prevalence of congenital genetic diseases. The COVID-19 pandemic has further accelerated this growth due to heightened demand for testing to mitigate prenatal complications. Government initiatives to reduce healthcare burdens and the introduction of innovative products by market players are also expected to enhance market expansion. However, challenges such as ethical concerns, high costs, and regulatory hurdles may impede the market's growth trajectory.

Market Size of Preimplantation Genetic Testing Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Preimplantation Genetic Testing Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 10.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Preimplantation Genetic Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Preimplantation Genetic Testing Market Analysis

The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period.

During COVID-19, there was an increasing adoption of the preimplantation of genetic testing, which is expected to drive the market's growth. The NCBI article published in October 2021 mentioned preimplantation genetic testing and embryologist specialization provided safety and assisted reproduction process have not negatively impacted patients with a previous record of COVID-19 infection. However, according to another NCBI article published in September 2022, women with COVID-19 during Pregnancy might have a higher risk of obstetrical and neonatal complications. Such risk of pre-natal complications in the infected patients boosted the demand for preimplantation genetic testing during the pandemic. Thus, the COVID-19 pandemic has increased the market's growth, which is expected to follow the same traction during the forecast period of the study.

The primary factor attributing to the market's growth is a rising awareness among parents regarding advancements in diagnostics, with a massive volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome and common pediatric respiratory disorders such as pneumonia and asthma has been observed in recent years. As per the NCBI article published in August 2021, the in-facility birth prevalence rate for congenital abnormalities in South Africa was 15.57 per 1,000 live births. Another NCBI published in September 2022 states that the live birth prevalence with Edwards syndrome in the UK ranges from 1 in 3600 to 1 in 10,000. These abnormalities occur almost exclusively in couples with hereditary disorders, which were observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and government initiatives to control the healthcare burden will likely drive the preimplantation genetic testing market.

Additionally, the increasing product launches by various market players are expected to boost market growth over the forecast period. For instance, Eurofins Genoma launched the niPGT-A, a non-non-invasive, in September 2022. It is an embryo biopsy-free, preimplantation genetic aneuploidy screening test. It provides IVF centers with access to a highly accurate alternative to traditional PGT-A testing.

Thus, the factors such as the growing prevalence of congenital genetic diseases and increasing product launches are expected to contribute to the market's growth over the forecast period. However, the small size of the study population and ethical concerns, costly testing procedures, and unfavorable regulatory framework and challenges during the development stage may restrain the market's growth over the forecast period.

Preimplantation Genetic Testing Industry Segmentation

As per the scope of the report, preimplantation genetic testing is the genetic profiling of embryos employed before implantation in IVF workflow, and sometimes even of oocytes before fertilization for a successful pregnancy. These tests help make the right decision for couples at risk of hereditary disorders, whether to terminate the pregnancy or not, by detecting the presence of disease during gestation. These tests also benefit women in IVF cycles who faced miscarriages earlier or those who had the last pregnancy with an abnormality in chromosomes. The Preimplantation Genetic Testing Market is segmented by test type( Preimplantation Genetic Diagnosis, Preimplantation Genetic screening), products and services (instruments, reagents, and consumables, software and services), application (HLA Typing, IVF Prognosis, Aneuploidy Screening, and other applications), end user (hospitals and diagnostic labs, maternity centers, and fertility clinics and other end users), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value in (USD million) for the above segments.

By Test Type
Preimplantation Genetic Diagnosis (PGD)
Preimplantation Genetic Screening (PGS)
By Product and Service
Instruments
Reagents and Consumables
Software and Services
By Application
HLA Typing
IVF Prognosis
Aneuploidy Screening
Other Applications
By End User
Hospitals and Diagnostic Labs
Maternity Centers and Fertility Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Preimplantation Genetic Testing Market Size Summary

The preimplantation genetic testing market is poised for significant growth, driven by increasing awareness among parents about advancements in diagnostics and the rising prevalence of congenital genetic diseases. The COVID-19 pandemic has further accelerated this growth, as it highlighted the importance of preimplantation genetic testing to mitigate prenatal complications in infected patients. The market is also benefiting from the growing demand for earlier diagnosis and government initiatives aimed at reducing healthcare burdens. The introduction of innovative products, such as non-invasive testing methods, is expected to enhance market expansion. However, challenges such as ethical concerns, high costs, and regulatory hurdles may pose constraints to market growth.

The IVF prognosis segment is anticipated to capture a substantial share of the preimplantation genetic testing market, fueled by the increasing number of IVF procedures and the rising incidence of infertility. North America is expected to lead the market, supported by a high prevalence of genetic disorders and active participation from key market players. The region's growth is further bolstered by partnerships and collaborations aimed at developing advanced genetic testing solutions. The competitive landscape is characterized by major players focusing on research and development, alongside strategic product launches, to maintain their market dominance.

Explore More

Preimplantation Genetic Testing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome

      2. 1.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices

    3. 1.3 Market Restraints

      1. 1.3.1 Small Size of Study Population and Ethical Concerns

      2. 1.3.2 Highly Expensive Testing Procedures

      3. 1.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Test Type

      1. 2.1.1 Preimplantation Genetic Diagnosis (PGD)

      2. 2.1.2 Preimplantation Genetic Screening (PGS)

    2. 2.2 By Product and Service

      1. 2.2.1 Instruments

      2. 2.2.2 Reagents and Consumables

      3. 2.2.3 Software and Services

    3. 2.3 By Application

      1. 2.3.1 HLA Typing

      2. 2.3.2 IVF Prognosis

      3. 2.3.3 Aneuploidy Screening

      4. 2.3.4 Other Applications

    4. 2.4 By End User

      1. 2.4.1 Hospitals and Diagnostic Labs

      2. 2.4.2 Maternity Centers and Fertility Clinics

      3. 2.4.3 Other End Users

    5. 2.5 Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South Korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Preimplantation Genetic Testing Market Size FAQs

The Preimplantation Genetic Testing Market is projected to register a CAGR of 10.5% during the forecast period (2024-2029)

Illumina Inc, Thermo Fisher Scientific Inc, PerkinElmer Inc, Bioarray S L and Cooper Surgical are the major companies operating in the Preimplantation Genetic Testing Market.

Preimplantation Genetic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)